Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $23.30

Shares of Rapport Therapeutics (NASDAQ:RAPP) gapped up prior to trading on Friday . The stock had previously closed at $23.30, but opened at $24.14. Rapport Therapeutics shares last traded at $23.82, with a volume of 22,449 shares.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on RAPP shares. TD Cowen began coverage on shares of Rapport Therapeutics in a research note on Tuesday. They issued a “buy” rating for the company. Stifel Nicolaus started coverage on Rapport Therapeutics in a research note on Tuesday. They set a “buy” rating and a $35.00 price target for the company. Finally, Jefferies Financial Group began coverage on Rapport Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $35.00 price objective on the stock.

Rapport Therapeutics Price Performance

Insider Activity at Rapport Therapeutics

In related news, Director James Healy acquired 44,032 shares of the stock in a transaction dated Monday, July 1st. The shares were acquired at an average price of $24.52 per share, for a total transaction of $1,079,664.64. Following the completion of the purchase, the director now owns 40,851 shares in the company, valued at approximately $1,001,666.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.